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With the supplement that accompanies this editorial and that
was published online in June 2019, the first part of the novel
Clinical Practice Guideline on Vascular Access for
Haemodialysis in Adults has now been finalized [1]. This docu-
ment was developed by European Renal Best Practice (ERBP),
the guidance body of the European Renal Association–
European Dialysis and Transplant Association in collaboration
with the Vascular Access Society, and is specifically devoted to
peri- and post-operative care of arteriovenous (AV) fistulas and
grafts.
In 1942, Willem Kolff sparked a major breakthrough in the
treatment of end-stage kidney disease with the development of
modern haemodialysis. Yet, with permanent vascular access
not available, and repeated dialysis sessions therefore impossi-
ble, the treatment remained confined to acute kidney injury for
many years. It took until the advent of the Quinton–Scribner
shunt in 1960, followed by the Cimino–Brescia AV fistula and
the AV graft, to allow chronic haemodialysis, preserving patient
life for longer periods and buying time to facilitate kidney
transplantation.
Regrettably, AV conduits are troublesome lifelines.
Inadequate maturation, progressive stenosis, access thrombosis
and infection make achieving sufficient blood flow for adequate
dialysis using an AV fistula or graft a continuous struggle in
many patients. Every professional who has been active in hae-
modialysis long enough will remember at least a few patients in
whom haemodialysis had to be abandoned due to lack of access.
They will remember manymore who underwent multiple inter-
ventions, often without ensuring adequate dialysis for pro-
longed periods.
Vascular access dysfunction leads to increased uraemic toxin
retention [2] and raises the subsequent risk of cardiovascular
events and death [3, 4]. It also affects quality of life and other
patient-oriented outcomes [5] such as itching, fatigue, cognitive
dysfunction and depression [5]. Multiple punctures of ‘difficult’
access systems and salvage interventions are painful and time
consuming, and thrombosis, haematoma, infiltration or infec-
tion may cause additional worry and stress.
Maintaining a functioning vascular access while minimizing
infection risk is critical for the well-being of patients treated
with haemodialysis. And so, evidence-based guidance on how
to promote AV fistula maturation, to maintain access adequacy
for dialysis and to minimize infection, in a way that is accept-
able to patients and their care providers is still needed.
Comprehensive vascular access guidelines are scarce. Only
the Spanish Multidisciplinary Group on Vascular Access [6]
and the European Society of Vascular Surgeons [7] offer current
recommendations on some of the topics covered by the novel
ERBP guideline. The current ERBP guideline thus deals with
questions that are seldom addressed, and does so from a
European perspective.
In 2007, European Best Practice Guidelines (EBPGs), the
predecessor of ERBP, published a set of recommendations re-
lated to haemodialysis to guide decisions on referral, assess-
ment, access choice, surveillance and management of
complications [8, 9]. The current ERBP guideline differs from
the previous one by a thorough change in scope and methodol-
ogy [9, 10]. Its development was the responsibility of a multidis-
ciplinary expert team, including two patients, that identified the
questions to be prioritized based on an extensive scoping proce-
dure with input from >1000 patients and health care workers;
another multidisciplinary team with >40 members, among
whomwere nephrologists, surgeons, interventional radiologists,
nurses and guideline methodologists, generated the recommen-
dations and their rationale. As such, the aim was not only to
support clinical decision making for any health care profes-
sional involved in vascular access care, but also to help patients
and care providers to gain insight, and accordingly facilitate
joint decision making in this field. In addition, development of
this guideline followed a rigorous process of evidence review
and appraisal based on the systematic reviews of results from
clinical trials and observational data, where necessary. This
structured approach was modelled after the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) system, which ascribes grades of strength for each
recommendation and the certainty of the underlying evidence
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(Table 1) [11]. It requires balancing all outcomes, both benefits
and harms, and considering variability in patient preference. An
attempt to adhere to increasingly stringent guideline develop-
ment methodology has required certain sacrifices in terms of
scope. As a result, the current guideline does not necessarily
cover the same topics as the previous version. Some are shared,
but some were archived in favour of new questions prioritized
by both health care providers and the patients they care for [12].
MAIN POINTS OF INTEREST
AV fistulas are separated from AV grafts throughout the guide-
line (Table 2). This reflects differences between these access
types in the available evidence for the various outcomes. In
Europe, AV grafts remain less popular alternatives to AV fistu-
las than central venous catheters, although outcomes of grafts
in observational studies are usually better than those of cathe-
ters [13–15]. The latter will be covered by a second part of the
guideline, under development as the current guideline went to
press, as will be access choice.
The recommendations also distinguish between maturation
and patency, two different but often confused concepts defining
access adequacy. Maturation can be described as the develop-
mental process an access undergoes from construction until
readiness for dialysis. It is a time during which the draining fis-
tula vein enlarges and thickens and blood flow increases.
Patency refers to the AV access being able to result in reliable
dialysis sessions over a longer-term period. Because maturation
problems in the first months may result from different patho-
physiological mechanisms than patency problems in the longer
term, the two issues were considered in separate chapters.
Of the 32 graded statements, only 5 were strong recommen-
dations; none could be supported with Level A and only four
with Level B evidence (Table 2). The remaining 28 recommen-
dations are supported by lower-grade evidence, offering less
certainty as to the expected benefits and harms of different
strategies. These low levels of evidence are emblematic of vascu-
lar access research and often stem from heterogeneity in study
design, insufficient power to detect important effects, poor ex-
ternal validity and the diversity and variable relevance of chosen
outcomes [16].
It is impossible to summarize the full extent of the guideline
in this editorial. For this, the reader is referred to the full text,
which discusses the evidence base thoroughly and objectively,
and details how it was interpreted and translated into
recommendations.
However, we wanted to highlight the strongest recommen-
dations and the elements that led to their formulation.
Two recommendations graded 1B discuss the timing of the
first cannulation. Recommendation 6.2 discourages the punc-
ture of AV fistulas before the second week after their creation. It
is based on eight observational studies using various cut-off
points for earliest access cannulation. For all cut-off points later
than 14 days after creation, there was either no clear difference
between earlier and later cannulation or results were inconsis-
tent. In contrast, a large well-conducted cohort study from the
Dialysis Outcomes Practice Patterns Study indicated an almost
2-fold increased risk of subsequent fistula failure for AV fistulas
cannulated before rather than >14 days after fistula creation.
Although there is no randomized controlled trial (RCT) to rely
on, the evidence base was upgraded from low to moderate be-
cause of the size of the effect. There was no difference for AV
fistulas cannulated before or after 28 days [17]. Two additional
recommendations suggest deferring cannulation for 4 weeks
and avoiding cannulation between 2 and 4 weeks unless this
can avoid placement of a central venous catheter
(Recommendations 6.1 and 6.3); the underlying evidence base
is weaker than for Recommendation 6.2.
Recommendation 6.4 on AV grafts is also graded 1B and
favours cannulation before 14 days after graft insertion over
Table 1. GRADE system for deﬁning the strength of the recommendation and certainty of the evidence
Implications
Grade Patients Clinicians Policy
1—strong, ‘We recommend’ Most people in your situation would want
the recommended course of action, only a
small proportion would not
Most patients should receive the
recommended course of action
The recommendation can be
adopted as a policy in most
situations
2—weak, ‘We suggest’ Most people in your situation would want
the recommended course of action, but
many would not
You should recognize that differ-
ent choices will be appropriate
for different patients
You must help each patient to ar-
rive at a management decision
consistent with her or his values
and preferences
Policymaking will require sub-
stantial debate and involve-
ment of many stakeholders
Grade Quality level Definition
A High We are conﬁdent that the true effects lie close to that of the
estimates of the effect
B Moderate The true effects are likely to be close to the estimates of the effects, but
there is a possibility that they are substantially different
C Low The true effects might be substantially different from the estimates
of effects
D Very low The estimates are very uncertain and often will be far from the truth
Modiﬁed from Guyatt et al. [11].
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catheter placement, provided the surgical wound has healed
and the graft has been designed specifically for early cannula-
tion. Although RCTs in this area are missing, this statement is
supported by a subanalysis of a prospective multicentre study
showing no difference between early (<72 h) and late cannula-
tion (>21 days) with early cannulation devices [18].
Recommendation 5.1 (labelled 1C) strongly supports peri-
operative antibiotic prophylaxis for AV grafts based on two
RCTs indicating an average 5% and 30% risk reduction [19, 20].
Because of the lack of evidence for AV fistulas, recommenda-
tions for that option were based on a review by the National
Institute for Health and Care Excellence on antibiotic prophy-
laxis during surgery [21]. Two additional low-strength, low-evi-
dence recommendations were generated, suggesting antibiotic
prophylaxis only for complex and not for simple AV fistula
procedures.
Another recommendation (8.4) advises against combining
high-dose aspirin and clopidogrel or other antiplatelet agents
with warfarin in patients with AV grafts, based on two RCTs
that found no improvement in graft outcome but had to be ter-
minated early for excessive bleeding risk [22, 23].
A last strong recommendation (10.2) was covered by very-
low-certainty evidence (1D) and disfavours the use of blunt
needles except for buttonhole cannulation of AV fistulas. There
was only one RCT including 35 participants directly comparing
sharp versus blunt needles in the buttonhole technique, which
did not allow favouring either one or the other [24].
Alongside specific recommendations, the guideline also con-
tains suggestions for clinical practice, which are based on com-
mon sense but not supported by a formal evidence review. This
allows offering advice about clinically important measures
when evidence is lacking. The recommendation set 6.1–6.3 on
Table 2. Summary of the content of the recommendations
Recommendation
number
Type of intervention Fistula/graft Strength Evidence level Target
1.1 Medical Fistula 2 C Maturation
1.2 Medical Fistula 2 C Maturation
1.3 Medical Fistula 2 C Maturation
1.4 Medical Fistula – D Maturation
2.1 Surg/Endovasc Fistula 2 C Maturation
2.2 Surg/Endovasc Fistula 2 C Maturation
3.1 Surg/Endovasc Fistula 2 D Maturation
4.1 Patient role Fistula 2 C Maturation
4.2 Patient role Fistula – D Maturation
5.1 Medical Graft 1 C Infection
5.2 Medical Both 2 D Infection
5.3 Medical Both 2 D Infection
6.1 Cannulation Fistula 2 C Timing
6.2 Cannulation Fistula 1 B Timing
6.3 Cannulation Fistula 2 C Timing
6.4 Cannulation Graft 1 B Timing
6.5 Cannulation Graft 2 B Timing
7.1 Surveillance Fistula 2 C Stenosis
7.2 Surveillance Graft 2 C Stenosis
8.1 Medical Fistula 2 C Patency
8.2 Medical Fistula 2 C Patency
8.3 Medical Fistula – D Patency
8.4 Medical Graft 1 C Patency
8.5 Medical Graft 2 C Patency
8.6 Medical Graft – D Patency
9.1 Cannulation Fistula 2 D Technique
9.2 Cannulation Fistula 2 D Technique
10.1 Cannulation Fistula 2 C Needle type
10.2 Cannulation Fistula 1 D Needle type
11.1 Surg/Endovasc Fistula 2 D Timing
11.2 Surg/Endovasc Fistula 2 D Timing
12.1 Surg/Endovasc Both 2 B Type of intervention
Summary Medical: 13
Surg/Endovasc: 6
Patient role: 2
Cannulation: 9
Surveillance: 2
Fistula: 22
Graft: 7
Both: 3
1: 5
2: 23
–: 4
A: 0
B: 4
C: 16
D: 12
Maturation: 9
Infection: 3
Timing: 7
Stenosis: 2
Patency: 6
Technique: 2
Needle type: 2
Type of
intervention: 1
Surg/Endovasc, surgery/endovascular.
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first cannulation of AV fistulas discussed above is accompanied
by some practical advice, e.g. the suggestion to use single-needle
dialysis as an early intermediate measure, allowing dialysis in
smaller fistulas with adequate flow without jeopardizing their
integrity.
Guidelines are often criticized for failing to provide clear ad-
vice for each topic covered. Largely limited by the state of the
evidence, the novel ERBP guideline may fall into that category.
It reflects the boundaries of what we know and the commitment
of the guideline group to communicate that clearly to the user.
In doing so, it fulfils another role, which is to highlight the gaps
in knowledge and encourage the right research to be done to
bridge them. This will require harmonization of outcome mea-
surement, allowing better comparisons between different stud-
ies and their aggregation into reliable systematic reviews.
Current initiatives such as the Standardized Outcomes in
Nephrology and the Kidney Health Initiative are to be
applauded in that respect and may help improve the compara-
bility of study results in the future. It also appears essential from
the guideline development perspective that, in developing those
studies, patients, as central stakeholders, are involved in defin-
ing the protocol structure and the endpoints of relevance to
them.
In conclusion, in parallel with this editorial, the novel ERBP
guideline on vascular access has been published. It is the result
of a group effort by a multidisciplinary team to comprehen-
sively review and interpret current evidence on several high-pri-
ority topics. We hope it will assist the professional community
in making decisions about vascular access processes, pathways
and care; help patients and care providers gain insight and facil-
itate joint decision making in this field.
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